2026 NPPES data Endocrinology, Diabetes & Metabolism Physician NPI 1073715165 MD
Verify on CMS →

STACIE BINGAMAN, MD

Endocrinology, Diabetes & Metabolism Physician in ARLINGTON, Texas. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.

Federal data — no proprietary rating. PlainDoctor publishes the actual CMS NPPES and Medicare records — NPI registration, specialty, practice location, and prescribing data — without a composite score or editorial opinion on top. Every field traces to a federal source.
Prescribing volume
632
Medicare Part D claims · 107 beneficiaries · Endocrinology, Diabetes & Metabolism Physician avg: 3K
Generic prescribing
57%
generic claims · 43% brand-name · higher generic rates reduce patient out-of-pocket costs
MIPS score
91.9639/100
▲ 9 pts above national avg 83.1 · [object Object]

What the federal data shows

STACIE BINGAMAN, MD reported a CMS MIPS final score of 91.9639/100 — above the 83.1 national average — and filed 632 Medicare Part D claims in 2023.

91.9639/100
MIPS score · +9 vs avg
632
Part D claims, 2023
57%
generic prescribing
Likely
board-certified (heuristic)

Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.

STACIE BINGAMAN, MD's MIPS score vs every scored U.S. clinician

CMS Merit-based Incentive Payment System (MIPS) final score, 2023 — the federal quality measure

92 Top 37% higher than 63% of 477,587 scored providers

0–10: 8,684 scored providers (2%). Below this entry. 10–20: 3,008 scored providers (1%). Below this entry. 20–30: 3,069 scored providers (1%). Below this entry. 30–40: 2,746 scored providers (1%). Below this entry. 40–50: 2,928 scored providers (1%). Below this entry. 50–60: 5,882 scored providers (1%). Below this entry. 60–70: 13,906 scored providers (3%). Below this entry. 70–80: 118,074 scored providers (25%). Below this entry. 80–90: 129,887 scored providers (27%). Below this entry. 90–100: 189,403 scored providers (40%). This entry sits in this band. This provider 0 100 every MIPS-scored clinician, bucketed by value

Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Merit-based Incentive Payment System (MIPS) · 2023

Board certification likely (heuristic — not verified)

STACIE BINGAMAN, MD practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting + 2 hospital affiliations — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).

What does the federal data show about STACIE BINGAMAN, MD?

High performer (top quartile)

NPI registry status

Active

Issued 06/01/2007

NPI 1073715165

Primary specialty

Endocrinology, Diabetes & Metabolism Physician

Mid-sized

7,852 US NPIs in this specialty

Medicare Part D claims

632 76% vs specialty avg

2023 prescription claims

Specialty avg: 2,639

MIPS final score

91.9639/100 8.863900000000001% pts

Exceptional band

vs 83.1 national avg

Specialty distribution in Texas

How Endocrinology, Diabetes & Metabolism Physician compares to other specialties among Texas providers

Texas providers

Endocrinology, Diabetes & Metabolism Physician share within Texas

1. Endocrinology, Diabetes & Metabolism Physician42%2. Internal medicine21%3. Family medicine17%4. Surgical12%5. Pediatric8%
Endocrinology, Diabetes & Metabolism Physician share within Texas

Medicare quality performance — MIPS

STACIE BINGAMAN, MD's 2023 MIPS final score plotted against the Endocrinology, Diabetes & Metabolism Physician national average

High performer (top quartile)
MIPS Final Score
91.9639/100
vs 83.1 national avg · 2023 performance year

MIPS final score (Endocrinology, Diabetes & Metabolism Physician) — 91.9639/100 vs national avg 83.1

0%100%National avg83%92%
MIPS final score (Endocrinology, Diabetes & Metabolism Physician) — 91.9639/100 vs national avg 83.1

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

STACIE BINGAMAN, MD appears in the CMS NPPES registry as a Endocrinology, Diabetes & Metabolism Physician provider holding MD credentials at 400 W ARBROOK BLVD STE 300, ARLINGTON, TX, 76014, with a listed phone of (972) 647-8404. NPI 1073715165 was issued on 06/01/2007. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what BINGAMAN most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.

Medicare Part D records for calendar year 2023 show 632 prescription claims written by this provider, covering 107 Medicare beneficiaries and totaling roughly $400K in drug spend, split 43% brand-name and 57% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 91.9639/100 for the 2023 performance year (Quality 89.7864, Cost 56.8144), compared with the national average of 83.1.

Endocrinology, Diabetes & Metabolism Physician is a mid-sized specialty nationwide, with 7,852 enrolled providers across 54 states and an average of 2,639 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

400 W ARBROOK BLVD STE 300
ARLINGTON, TX 76014

Provider Details

NPI 1073715165
Specialty Endocrinology, Diabetes & Metabolism Physician
Credentials MD
Gender Female
NPI Issued 06/01/2007

CMS Quality Score (MIPS)

Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.

91.9639
Final Score
Avg: 83.1
89.7864
Quality
56.8144
Cost
100
Promoting Interoperability

Reporting: Group practice

Hospital and facility affiliations

Facilities where STACIE BINGAMAN, MD bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" — a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.

ACCLAIM PHYSICIAN GROUP INC
FORT WORTH, TX
IU HEALTH MEDICAL GROUP LLC
AVON, IN

Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).

License & disciplinary context — Texas TMB 2023 annual report

Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~77K Texas medical licensees in 2023 — they are NOT specific to STACIE BINGAMAN, MD. To verify STACIE BINGAMAN, MD's current license status, search the TMB public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.

344
Total board actions, Texas 2023
Across 334 cases
4.47
Actions per 1,000 licensees
Texas statewide rate
probation
Most common action type
94 cases

TMB publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the Texas disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.

Brand vs generic prescribing mix · Above average

STACIE BINGAMAN, MD — brand share 43.0%
Specialty average (est.)

43% brand-name claims vs 57% generic, on 632 2023 Medicare Part D claims.

The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

632
Total Claims
$400K
Total Drug Cost
107
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
1,489
Total Day Supply
43,812
Brand vs Generic
43% brand / 57% generic
Brand Drug Cost
$361K
Generic Drug Cost
$17K

Patient Demographics

Average Patient Age
64.1 years
Avg HCC Risk Score
1.92
Gender Split
79% female / 21% male
Age Distribution
<65: 42, 65-74: 50, 75-84: N/A, 85+: N/A

Top Prescribed Drugs (Medicare Part D)

Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.

What STACIE BINGAMAN, MD prescribes most

Top Medicare Part D drugs by claim count, 2023

claims
Source CMS Medicare Part D Prescriber Public Use File As of 2023
Drug Claims
Levothyroxine Sodium
68
Trulicity
Dulaglutide
50
Methimazole
34
Atorvastatin Calcium
24
Metformin Hcl
18
Calcitriol
16
Gabapentin
15
Ozempic
Semaglutide
15
Jardiance
Empagliflozin
13
Lisinopril
12

* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.

Endocrinology, Diabetes & Metabolism Physician Overview

How STACIE BINGAMAN, MD fits within the Endocrinology, Diabetes & Metabolism Physician landscape nationally.

7,852
Endocrinology, Diabetes & Metabolism Physician Providers in US
54
States with Endocrinology, Diabetes & Metabolism Physician
2,639
Avg Claims per Provider

STACIE BINGAMAN, MD's 632 claims are below the specialty average of 2,639.

Nearby Endocrinology, Diabetes & Metabolism Physician Providers in Texas

Other clinicians with the same primary specialty enrolled in Texas, drawn from the same CMS NPPES roster as BINGAMAN.

Compare Endocrinology, Diabetes & Metabolism Physician nationally: see state-by-state distribution →

Frequently Asked Questions

What is STACIE BINGAMAN, MD's specialty?
STACIE BINGAMAN, MD specializes in Endocrinology, Diabetes & Metabolism Physician and practices in ARLINGTON, Texas. Credentials: MD.
How much does STACIE BINGAMAN, MD prescribe under Medicare Part D?
In 2023, STACIE BINGAMAN, MD wrote 632 Medicare Part D claims totaling $400K in drug costs for 107 beneficiaries.
What is STACIE BINGAMAN, MD's Medicare quality score?
STACIE BINGAMAN, MD has a CMS MIPS Final Score of 91.9639/100 (Quality: 89.7864, Cost: 56.8144). The national average MIPS Final Score is 83.1. Source: CMS Merit-based Incentive Payment System (MIPS) 2023.
Where is STACIE BINGAMAN, MD located?
STACIE BINGAMAN, MD is located at 400 W ARBROOK BLVD STE 300, ARLINGTON, TX, 76014. Phone: (972) 647-8404.
What is STACIE BINGAMAN, MD's NPI number?
STACIE BINGAMAN, MD's National Provider Identifier (NPI) is 1073715165, issued on 06/01/2007.
Does STACIE BINGAMAN, MD prescribe more brand-name or generic drugs?
STACIE BINGAMAN, MD's prescribing is 43% brand-name and 57% generic drugs by claim count, with $361K in brand drug costs.
How many Endocrinology, Diabetes & Metabolism Physician providers are there in the US?
There are 7,852 Endocrinology, Diabetes & Metabolism Physician providers across 54 states in the US. The average Endocrinology, Diabetes & Metabolism Physician provider writes 2,639 Medicare Part D claims per year.
What drugs does STACIE BINGAMAN, MD prescribe most often?
Based on 2023 Medicare Part D data, STACIE BINGAMAN, MD's most frequently prescribed drugs include Levothyroxine Sodium, Trulicity, Methimazole. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does STACIE BINGAMAN, MD accept Medicare?
STACIE BINGAMAN, MD appears in CMS Medicare data with 632 Part D claims and 107 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify STACIE BINGAMAN, MD's credentials?
STACIE BINGAMAN, MD's NPI is 1073715165 with credentials MD. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Quality Performance
CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology